Janssen

Johnson & Johnson

GLEIF, search.gleif.org

NCT06527690

Collaborator, Phase 2, Withdrawn, 2025, 0 people, 30 Jul 2024, clinicaltrials.gov

NCT06392841

Collaborator, Phase 2, Withdrawn, 2025, 0 people, 30 Apr 2024, clinicaltrials.gov

NCT06251076

Collaborator, Phase 4, Recruiting, 2024, 15 people, 9 Feb 2024, clinicaltrials.gov

NCT05998642

Collaborator, Phase 2, Recruiting, 2024, 30 people, 21 Aug 2023, clinicaltrials.gov

NCT05408026

Collaborator, Phase 1/2, Withdrawn, 2022, 0 people, 7 Jun 2022, clinicaltrials.gov

NCT04812366

Collaborator, Phase 2, Recruiting, 2021, 315 people, 23 Mar 2021, clinicaltrials.gov

NCT04700176

Collaborator, Phase 2, Terminated, 2022, 1 person, 7 Jan 2021, clinicaltrials.gov

NCT04263480

Collaborator, Phase 2, Active, not recruiting, 2021, 99 people, 10 Feb 2020, clinicaltrials.gov

NCT04166565

Collaborator, Phase 2, Active, not recruiting, 2019, 41 people, 18 Nov 2019, clinicaltrials.gov

NCT04113018

Collaborator, Phase 2, Active, not recruiting, 2020, 39 people, 2 Oct 2019, clinicaltrials.gov

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

Collaborator, Phase 2, Completed, 2019, 20 people, 12 Aug 2019, clinicaltrials.gov

NCT04006288

Collaborator, Phase 4, Completed, 2019, 90 people, 5 Jul 2019, clinicaltrials.gov

NCT03984838

Collaborator, Phase 1, Completed, 2019, 16 people, 13 Jun 2019, clinicaltrials.gov

NCT03942224

Collaborator, Phase 2, Status unknown, 2019, 49 people, 8 May 2019, clinicaltrials.gov

NCT03766581

Collaborator, Phase 2, Completed, 2019, 2,366 people, 6 Dec 2018, clinicaltrials.gov

NCT03734198

Collaborator, Phase 2, Active, not recruiting, 2018, 29 people, 7 Nov 2018, clinicaltrials.gov

NCT03732703

Collaborator, Phase 1/2, Completed, 2019, 103 people, 7 Nov 2018, clinicaltrials.gov

NCT03695744

Collaborator, Phase 2, Status unknown, 2019, 27 people, 4 Oct 2018, clinicaltrials.gov

NCT03590652

Collaborator, Phase 2, Terminated, 2018, 23 people, 18 Jul 2018, clinicaltrials.gov

NCT03188172

Collaborator, Phase 2, Status unknown, 2017, 95 people, 15 Jun 2017, clinicaltrials.gov

Prospective cohort study for digital health research in Germany (DigiHero): objectives, design and baseline characteristics

Fees or honoraria, Grants or research support, 8 Oct 2026, pubmed.ncbi.nlm.nih.gov

Neurologic Stability During Tafamidis Treatment in Transthyretin Amyloidosis with a Mixed Phenotype: A Multicenter Real-World Study

Consulting or advice, Fees or honoraria, Grants or research support, 7 Oct 2026, pubmed.ncbi.nlm.nih.gov

Bariatric surgery and risk of dementia and Parkinson's disease in patients with obesity

Grants or research support, 7 Oct 2026, pubmed.ncbi.nlm.nih.gov

Oral microbial nitrate metabolism is associated with lower prevalence of prediabetes

Consulting or advice, Board or leadership role, 7 Oct 2026, pubmed.ncbi.nlm.nih.gov

Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)

Grants or research support, 6 Oct 2026, pubmed.ncbi.nlm.nih.gov

Single-component imaging and ultrasound-based tools for the assessment of fracture risk

Fees or honoraria, 1 Oct 2026, pubmed.ncbi.nlm.nih.gov

Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial

Fees or honoraria, 1 Oct 2026, pubmed.ncbi.nlm.nih.gov

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change

Consulting or advice, Fees or honoraria, Grants or research support, 1 Oct 2026, pubmed.ncbi.nlm.nih.gov

Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes

Fees or honoraria, 28 Sept 2026, pubmed.ncbi.nlm.nih.gov

Economic evaluation of NT-proBNP testing plus standard clinical assessment versus standard clinical assessment alone for the prevention of heart failure in older adults with type 2 diabetes

Consulting or advice, 28 Sept 2026, pubmed.ncbi.nlm.nih.gov

Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility testing from genetics clinics to the general population

Consulting or advice, Board or leadership role, 25 Sept 2026, pubmed.ncbi.nlm.nih.gov

Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study

Fees or honoraria, 22 Sept 2026, pubmed.ncbi.nlm.nih.gov

Association of tirzepatide versus Glucagon-Like Peptide-1 receptor agonists with oral and periodontal outcomes in patients with type 2 Diabetes: A Global propensity Score-Matched cohort study

Consulting or advice, Fees or honoraria, Grants or research support, Board or leadership role, 20 Sept 2026, pubmed.ncbi.nlm.nih.gov

No association between Epstein-Barr Virus serostatus and infection-related mortality in 9,429 British adults: a UK Biobank study

Fees or honoraria, 17 Sept 2026, pubmed.ncbi.nlm.nih.gov

The machine-learning classifier ALLCatchR2 identifies 20 T-ALL subtypes across cohorts and age groups

Fees or honoraria, 14 Sept 2026, pubmed.ncbi.nlm.nih.gov

Linking cognitive variability and Alzheimer's disease biomarkers by neurocognitive status

Grants or research support, 13 Sept 2026, pubmed.ncbi.nlm.nih.gov

Glycemic Markers and Cardiometabolic Multiple Long-Term Conditions: Comparative Roles of Glycated Hemoglobin and Fasting Plasma Glucose in the English Longitudinal Study of Ageing

Fees or honoraria, 12 Sept 2026, pubmed.ncbi.nlm.nih.gov

Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy

Fees or honoraria, 11 Sept 2026, pubmed.ncbi.nlm.nih.gov

Advances from Traditional Clinical Decision Support Tools to Machine Learning Applications in Primary Prevention of Thromboembolic Disorders

Grants or research support, 9 Sept 2026, pubmed.ncbi.nlm.nih.gov

Observational study on initiation of dapagliflozin in heart failure with reduced ejection fraction in the United Kingdom

Grants or research support, 8 Sept 2026, pubmed.ncbi.nlm.nih.gov